ipilimumab
ipilimumab: 128 clinical trials tracked.
ipilimumab evidence translation
What we can confirm
128 tracked trials
What it means
What to watch
Prepared research question
What is verified about ipilimumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 11 study sponsors
Related indications
Clinical Trial Registry Records (128)showing 10 most recent
A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)
Primary endpoint: Safety and adverse events (AEs)
A Phase Ib/II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)
Primary endpoint: Progression-free survival (PFS) (Phase Ib acceptable dose participants and Phase II participants)
Phase III Double Blinded Trial of Immune-Based Therapy With a Live Biotherapeutic MO-03 or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial]
Primary endpoint: Progression-free survival (PFS)
REMEDY-RCC: Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell Carcinoma - A Prospective, Exploratory, Single-Center Study
Primary endpoint: Objective Response Rate(ORR)
A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
Primary endpoint: Objective Response Rate (ORR)
A Phase 1a/1b Basket Trial of BMS-986504 With Standard-of-Care Therapy For Patients With Select Metastatic MTAP-deleted Solid Tumors
Primary endpoint: determine a recommended phase II dose (RP2D) of BMS-986504 in combination with standard-of-care therapy
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC)
Primary endpoint: Number of participants with adverse events (AEs)
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Primary endpoint: Number of participants with adverse events (AEs)
Phase III Randomized Trial of IO-Based Systemic Treatment +/- Liver SBRT in Hepatocellular Cancer With Macrovascular Invasion (HELIO-RT)
Primary endpoint: Overall survival (OS)
A Prospective Observational Study Comparing Chemotherapy Plus Pembrolizumab Versus Nivolumab Plus Ipilimumab With Chemotherapy in Patients With Metastatic Non-Small Cell Lung Cancer and PD-L1 Expression Below 50%
Primary endpoint: Progression-Free Survival (PFS)